Tagrisso granted priority review in the us for the adjuvant treatment of patients with early-stage egfr-mutated lung cancer

Astrazeneca’s tagrisso® (osimertinib) has received acceptance for its supplemental new drug application (snda) and has also been granted priority revi

ARCH Ratings Summary

ARCH Quant Ranking